These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 6682863)

  • 1. Trace analysis for cis-platinum anti-cancer drugs via LCEC.
    Krull IS; Ding XD; Braverman S; Selavka C; Hochberg F; Sternson LA
    J Chromatogr Sci; 1983 Apr; 21(4):166-73. PubMed ID: 6682863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of platinum-containing drugs in human plasma by liquid chromatography with reductive electrochemical detection.
    Parsons PJ; Morrison PF; LeRoy AF
    J Chromatogr; 1987 Jan; 385():323-35. PubMed ID: 3558589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP).
    Kralovánszky J; Prajda N; Kerpel-Fronius S; Gál F; Kiss F
    Cancer Chemother Pharmacol; 1988; 21(1):40-4. PubMed ID: 3277733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.
    Sharma H; Thatcher N; Baer J; Zaki A; Smith A; McAucliffe CA; Crowther D; Owens S; Fox BW
    Cancer Chemother Pharmacol; 1983; 11(1):5-7. PubMed ID: 6349844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
    Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G
    Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid.
    Almotairy ARZ; Gandin V; Morrison L; Marzano C; Montagner D; Erxleben A
    J Inorg Biochem; 2017 Dec; 177():1-7. PubMed ID: 28918353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats.
    Láznícková A; Láznícek M; Kvĕtina J; Drobník J
    Cancer Chemother Pharmacol; 1986; 17(2):133-6. PubMed ID: 3521926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo and in vitro effectivity of some platinum complexes.
    Balázová E; Hrubisko M; Ujházy V
    Neoplasma; 1984; 31(6):641-7. PubMed ID: 6395026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera.
    Owens SE; Thatcher N; Sharma H; Adam N; Harrison R; Smith A; Zaki A; Baer JC; McAuliffe CA; Crowther D
    Cancer Chemother Pharmacol; 1985; 14(3):253-7. PubMed ID: 3888431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer.
    Pendyala L; Greco W; Cowens JW; Madajewicz S; Creaven PJ
    Cancer Chemother Pharmacol; 1983; 11(1):23-8. PubMed ID: 6883623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
    Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
    Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of four platinum cytostatics in rats.
    Láznícková A; Filipová M; Láznícek M; Drobník J; Svoboda D; Kvĕtina J
    Neoplasma; 1987; 34(2):173-81. PubMed ID: 3600883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
    Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
    Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics.
    Kim DK; Kim HT; Tai JH; Cho YB; Kim TS; Kim KH; Park JG; Hong WS
    Cancer Chemother Pharmacol; 1995; 37(1-2):1-6. PubMed ID: 7497577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the pharmacokinetics and metabolism of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) in the dog.
    Pendyala L; Cowens JW; Creaven PJ
    Cancer Treat Rep; 1982 Mar; 66(3):509-16. PubMed ID: 7060038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
    Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
    Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
    Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
    Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9).
    Schweitzer VG; Rarey KE; Dolan DF; Abrams G; Litterst CJ; Sheridan C
    Otolaryngol Head Neck Surg; 1986 Apr; 94(4):458-70. PubMed ID: 3086808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease.
    Thatcher N; Sharma H; Harrison R; Smith A; Zaki A; McAuliffe CA; Crowther D; Fox BW
    Cancer Chemother Pharmacol; 1982; 9(1):13-6. PubMed ID: 6890414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats.
    Ohno S; Strebel FR; Stephens LC; Siddik ZH; Makino M; Klostergaard J; Tomasovic SP; Khokhar AR; Bull JM
    Cancer Res; 1992 Aug; 52(15):4096-101. PubMed ID: 1638521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.